Krystal Biotech (KRYS) Price & Analysis

Compare

617 Followers

KRYS Stock Chart & Stats

$282.01

-$3.73(-2.33%)

At close: Jan 08 4:00 PM EST

$282.01

-$3.73(-2.33%)

Day’s Range― - ―

52-Week Range$122.80 - $295.98

Previous CloseN/A

Volume44.50K

Average Volume (3M)308.62K

Market Cap

$8.18B

Enterprise Value$4.54B

Total Cash (Recent Filing)$731.07M

Total Debt (Recent Filing)$9.51M

Price to Earnings (P/E)42.8

Beta0.72

Next Earnings

Mar 02, 2026

EPS Estimate

1.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.66

Shares Outstanding28,997,519

10 Day Avg. Volume330,148

30 Day Avg. Volume308,620

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.73

Price to Sales (P/S)15.42

P/FCF Ratio37.58

Enterprise Value/Market Cap0.56

Enterprise Value/Revenue12.18

Enterprise Value/Gross Profit12.97

Enterprise Value/Ebitda26.55

Forecast

1Y Price Target

$289.43

Price Target Upside2.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)7.73

Revenue Forecast (FY)$552.07M

Bulls Say, Bears Say

Bulls Say

Balance Sheet And Pipeline FundingA strong balance sheet supports advancement of multiple registrational programs and enables pursuit of a multi-product rare disease strategy without immediate financing risk.

International CommercializationGlobal launches of Vyjuvek in Europe and Japan combined with effective U.S. commercial execution create multi-region revenue momentum that could support broader rare-disease commercial expansion.

Platform ValidationInterim KB407 data demonstrating mutation-agnostic delivery and widespread CFTR protein expression in lung tissue validates the inhaled gene-delivery platform and supports potential use across multiple respiratory indications.

Bears Say

Durability Of Therapeutic EffectUncertainty about how long CFTR expression persists after redosing and whether observed expression will translate into meaningful lung function improvement poses a major risk for registrational success.

Financial Pressure And DilutionProjected increases in research and selling expenses coupled with potential increases in share count could pressure profitability and dilute earnings per share for existing investors.

Trial Execution And Measurement VariabilityReliance on bronchoscopic delivery and high variability in lung function measurements complicates interpretation of small-trial results and increases development execution risk.

Krystal Biotech News

Krystal Biotech price target raised to $336 from $320 at Citi

Citi raised the firm’s price target on Krystal Biotech (KRYS) to $336 from $320 and keeps a Buy...

5d ago

KRYS

Krystal Biotech price target raised to $306 from $202 at TD Cowen

TD Cowen raised the firm’s price target on Krystal Biotech (KRYS) to $306 from $202 and keeps a...

8d ago

KRYS

Krystal Biotech price target raised to $306 from $202 at TD Cowen

TD Cowen raised the firm’s price target on Krystal Biotech (KRYS) to $306 from $202 and keeps a...

8d ago

KRYS

Krystal Biotech price target raised to $288 from $272 at BofA

BofA raised the firm’s price target on Krystal Biotech (KRYS) to $288 from $272 and keeps a Buy...

8d ago

KRYS

Krystal Biotech price target raised to $320 from $309 at Citi

Citi raised the firm’s price target on Krystal Biotech (KRYS) to $320 from $309 and keeps a Buy...

8d ago

KRYS

Krystal Biotech price target raised to $288 from $217 at Clear Street

Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $288 from $217 and keeps a...

8d ago

KRYS

Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Krystal Biotech (KRYS) to $310 from $240 and keeps a...

8d ago

KRYS

Krystal Biotech announces interim update from highest dose cohort of CORAL-1

Krystal Biotech (KRYS) announced an interim clinical update from the highest dose cohort of CORAL-1, the company’s multi-center,...

9d ago

KRYS

Krystal Biotech price target raised to $272 from $255 at BofA

BofA analyst Alec Stranahan raised the firm’s price target on Krystal Biotech (KRYS) to $272 from $255 and...

11d ago

KRYS

Krystal Biotech upgraded to Buy from Neutral at Citi

Citi upgraded Krystal Biotech (KRYS) to Buy from Neutral with a price target of $309, up from $198....

11d ago

KRYS

Krystal Biotech outlines rare disease growth strategy update

Krystal Biotech ( ($KRYS) ) just unveiled an update. On January 11, 2026, Krystal Biotech reported selected preliminary,...

5d ago

KRYS

Early Proof-of-Concept and Platform Potential Drive Buy Rating on Krystal Biotech Despite Pending Lung Function Data

William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating today....

9d ago

KRYS

Krystal Biotech advances KB407 with positive CF trial data

Krystal Biotech ( ($KRYS) ) just unveiled an update. On January 8, 2026, Krystal Biotech reported positive interim...

9d ago

KRYS

Krystal Biotech announces resignation of longtime board member

Krystal Biotech ( ($KRYS) ) has issued an update. On December 22, 2025, Krystal Biotech announced that board...

25d ago

KRYS

KRYS FAQ

What was Krystal Biotech’s price range in the past 12 months?

Krystal Biotech lowest stock price was $122.80 and its highest was $295.98 in the past 12 months.

What is Krystal Biotech’s market cap?

Krystal Biotech’s market cap is $8.18B.

When is Krystal Biotech’s upcoming earnings report date?

Krystal Biotech’s upcoming earnings report date is Mar 02, 2026 which is in 44 days.

How were Krystal Biotech’s earnings last quarter?

Krystal Biotech released its earnings results on Nov 03, 2025. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $1.09 by $1.57.

Is Krystal Biotech overvalued?

According to Wall Street analysts Krystal Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Krystal Biotech pay dividends?

Krystal Biotech does not currently pay dividends.

What is Krystal Biotech’s EPS estimate?

Krystal Biotech’s EPS estimate is 1.58.

How many shares outstanding does Krystal Biotech have?

Krystal Biotech has 28,997,519 shares outstanding.

What happened to Krystal Biotech’s price movement after its last earnings report?

Krystal Biotech reported an EPS of $2.66 in its last earnings report, beating expectations of $1.09. Following the earnings report the stock price went up 0.172%.

Which hedge fund is a major shareholder of Krystal Biotech?

Currently, no hedge funds are holding shares in KRYS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Krystal Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.66%

Trailing 12-Months

Asset Growth

26.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Krystal Biotech

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech (KRYS) Earnings & Revenues

Historic Earnings Reports

KRYS Company Deck

KRYS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Krystal Biotech demonstrated strong financial performance with significant revenue growth and successful international expansion. However, challenges remain in achieving full market penetration and optimizing margins globally.View all KRYS earnings summaries

KRYS Stock 12 Month Forecast

Average Price Target

$289.43

▲(2.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","337":"$337","177.25":"$177.3","230.5":"$230.5","283.75":"$283.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$336.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":289.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$289.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$220.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,177.25,230.5,283.75,337],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,246.54,253.42153846153846,260.3030769230769,267.18461538461537,274.06615384615384,280.9476923076923,287.8292307692308,294.71076923076924,301.5923076923077,308.4738461538461,315.35538461538465,322.23692307692306,329.11846153846153,{"y":336,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,246.54,249.83923076923077,253.13846153846154,256.4376923076923,259.73692307692306,263.03615384615387,266.3353846153846,269.63461538461536,272.93384615384616,276.2330769230769,279.5323076923077,282.83153846153846,286.13076923076926,{"y":289.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,246.54,244.49846153846153,242.45692307692306,240.4153846153846,238.37384615384616,236.3323076923077,234.29076923076923,232.24923076923076,230.2076923076923,228.16615384615383,226.12461538461537,224.08307692307693,222.04153846153847,{"y":220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":156.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >